SIETES :: 93213 citas

Resultados de la búsqueda por BIOTECNOLOGÍA REFINAR BÚSQUEDA

1.

Hetland ML, Haavardsholm EA, Rudin A, Nordtröm D, Nurmohamed M, Gudbjornsson B, Lampa J, et al.. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:2 de diciembre. [Ref.ID 103805]

2.

Anónimo. Three new drugs for the prevention of migraine. Drug Ther Bull 2020;58:octubre. [Ref.ID 103746]

3.

Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]

4.

Parsons L. Roche’s Actemra fails in late-stage severe COVID-19 study. PMLiVE 2020:29 de julio. [Ref.ID 103699]

5.

Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]

6.

Vélez AM. La esposa del presidente de Pharmamar compra 220.000 títulos de la farmacéutica por un tercio de su valor de mercado . eldiario.es 2020:29 de junio. [Ref.ID 103677]

7.

Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]

8.

Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

9.

Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020;77:agosto. [Ref.ID 103656]

10.

Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

11.

Rejón >R. El dinero público empuja la investigación contra la COVID-19 sin garantía de que las patentes farmacéuticas permitan el acceso a esas medicinas. eldiario.es 2020:1 de mayo. [Ref.ID 103610]

12.

Mazzucato M, Torreele E. Cómo desarrollar una vacuna del Covid-19 para todos . Sinpermiso 2020:3 de mayo. [Ref.ID 103607]

13.

PM Group. Developing a COVID-19 vaccine. PMLiVE 2020:28 de abril. [Ref.ID 103606]

14.

PMG Group. Moderna submits application to advance coronavirus vaccine testing. PMLiVE 2020:28 de abril. [Ref.ID 103605]

15.

Rejón R. Sanidad incorpora dos nuevos medicamentos para aplicar como último recurso en pacientes graves de COVID-19 . eldiario.es 2020:18 de abril. [Ref.ID 103588]

16.

Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020;368:17 de marzo. [Ref.ID 103563]

17.

Taylor P. Did Trump offer CureVac $1bn for COVID-19 vaccine rights?. PMLiVE 2020:16 de marzo. [Ref.ID 103551]

18.

Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]

19.

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

20.

Parsons L. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following clearance from the Federal Trade Commission in the US. . PMLiVE 2019:17 de diciembre. [Ref.ID 103226]